Serum surfactant protein D as a predictive biomarker for the efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of the phase 3 trial in Japan
Abstract Background Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal disorder with a variable disease course. The recent advancement of antifibrotic therapy has increased the need for reliable and specific biomarkers. This study aimed to assess alveolar epithelial biomarkers as predictors...
Main Authors: | Kimiyuki Ikeda, Hirofumi Chiba, Hirotaka Nishikiori, Arata Azuma, Yasuhiro Kondoh, Takashi Ogura, Yoshio Taguchi, Masahito Ebina, Hiroki Sakaguchi, Shogo Miyazawa, Moritaka Suga, Yukihiko Sugiyama, Toshihiro Nukiwa, Shoji Kudoh, Hiroki Takahashi, Pirfenidone Clinical Study Group in Japan |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-11-01
|
Series: | Respiratory Research |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12931-020-01582-y |
Similar Items
-
The clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trial
by: Nakata Koichiro, et al.
Published: (2011-07-01) -
Application of Pirfenidone anti-fibrosis in ophthalmology
by: Xiao Yang, et al.
Published: (2013-08-01) -
Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment
by: Takahashi Hiroki, et al.
Published: (2011-10-01) -
No effect of pirfenidone treatment in fulminant bleomycin-induced pneumonitis
by: Elisabeth Bendstrup, et al.
Published: (2014-01-01) -
Evaluation of the efficacy of pirfenidone in progressive chronic hypersensitivity pneumonitis
by: Eman Shebl, et al.
Published: (2021-03-01)